Cannabinoid Hyperemesis Syndrome (CHS)
A paradoxical condition of cyclic vomiting in chronic, heavy cannabis users. Characterized by recurrent episodes of nausea, vomiting, and abdominal pain relieved by hot bathing.
In Depth
CHS is a poorly understood condition that contradicts cannabis's antiemetic properties. It occurs in a subset of long-term heavy users and is characterized by cyclical vomiting episodes lasting 24–48 hours, often with a prodromal phase of morning nausea. The pathophysiology may involve TRPV1 desensitization in the gut or hypothalamic temperature dysregulation. The only effective treatment is cannabis cessation. Hot showers/baths provide temporary relief, possibly through TRPV1 activation in the skin.
Related Terms
More in Clinical
Dravet Syndrome
A severe, treatment-resistant form of childhood epilepsy characterized by prolonged seizures, often triggered by fever, beginning in the first year of life.
Lennox-Gastaut Syndrome (LGS)
A severe form of childhood-onset epilepsy characterized by multiple seizure types, slow spike-wave EEG pattern, and cognitive impairment.
Epidiolex
The FDA-approved pharmaceutical formulation of purified cannabidiol (CBD), manufactured by GW Pharmaceuticals (now Jazz Pharmaceuticals). Approved in 2018 for Dravet syndrome and Lennox-Gastaut syndrome.
Dronabinol (Marinol)
A synthetic form of THC (Δ9-tetrahydrocannabinol) approved by the FDA for chemotherapy-induced nausea/vomiting and AIDS-related anorexia.
Nabilone (Cesamet)
A synthetic cannabinoid analogue of THC approved for chemotherapy-induced nausea and vomiting. More potent than dronabinol.